Below is a sampling of some of the companies that have graduated from the Commercialization Center for Innovation Technologies (CCIT).
3D Biotek is a biotechnology company focusing on commercialization of novel 3-dimentional (3-D) cell culture devises for use in stem cell, cell biology, tissue engineering, drug discovery, and medical device fields.
Accelalox is a privately held company developing therapies to treat musculoskeletal conditions. Our initial therapy will accelerate an enhance bone healing. This therapy will be used for bone fractures and spinal fusions to improve patient outcomes through accelerated healing and reduced complications.
Advaxis Inc. is a biotechnology company based upon the concept that in order to treat cancer and other diseases immunologically, it is best to use a modified infectious micro-organism to elicit the most profound immune response possible. It has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously. Unlike other therapeutic approaches, Advaxis' Listeria technology has been able to constantly demonstrate complete therapeutic responses resulting in complete tumor regression, even in the presence of immune tolerance. The company is the exclusive licensee of a broadly enabling platform technology for creating cancer vaccines and therapies for infectious diseases and other immune problems based upon genetically modified Listeria.
Aestus Therapeutics was founded in 2005 to take advantage of the vast amount of data created by high-throughput and genome-scale technologies. By integrating a broad spectrum of cutting edge technologies in novel ways, Aestus Therapeutics has intellectualized the pharmaceutical R&D process to create considerable value and new products for diseases with unmet medical needs.
Amicus Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule, orally administered drugs known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
Amicus is focused on three key strategic priorities:
- The Phase 3 development of its lead program, AT1001 (migalastat HCl) for the treatment of Fabry disease;
- The advancement of pharmacological chaperones used in combination with enzyme replacement therapies (ERT) for the treatment of lysosomal storage diseases; and
- The advancement of its lead pre-clinical programs that utilize its pharmacological chaperone technology for the treatment of diseases of neurodegeneration.
Since its inception in 2002, Amicus has assembled a world-class leadership team with proven expertise in drug discovery, development and commercialization. The Company completed an Initial Public Offering in May 2007 and trades on the NASDAQ National Market under the Ticker Symbol: FOLD. Amicus’ headquarters is located in Cranbury, NJ and has a research facility in San Diego, CA.
GENEWIZ Inc. is a global contract research organization (CRO) committed to advancing research productivity through rapid delivery of reliable, high-quality results, competitive prices, excellent project management, and easily accessible award-winning technical support.
GENEWIZ customers are supported by major investments in state-of-the-art facilities, rigorous quality systems based on Good Laboratory Practices (GLP), and highly-qualified scientific teams at the local, national, and international levels. GENEWIZ continuously innovates and stays current with the latest technologies in order to produce the best results and most convenient customer experience.
Serving the life science community for 11 years, GENEWIZ, Inc. is the #1 provider of Sanger DNA sequencing services, as well as the partner of choice for gene synthesis, molecular biology, genomic, and GLP-compliant regulatory services. Excelling in both science and customer support, customers depends on GENEWIZ to take ownership of the research and to complete it faster and more cost-efficiently through their scale and specialized expertise. GENEWIZ is proud to help advance the research of tens of thousands of scientists at leading academic, pharmaceutical, clinical, biotechnology, and government institutions.
The mission of GENEWIZ is to contribute to the advancement of life sciences and technologies by making research more productive and cost efficient through their scalable services.
The vision is to make GENEWIZ the partner of choice for life science research communities around the world. Together they can make a difference in the pursuit of scientific discoveries, better medicines, a greener environment, and abundant healthy food supplies.
In June 2011, GENEWIZ, Inc. and Biomatters announced a strategic partnership to align DNA-based services and analysis software. Click here for more information on this partnership.
Chromocell is a drug discovery company focused on the identification and development of novel therapeutics against the most complex and challenging drug targets. Their therapeutic programs leverage the ability of Chromovert technology to rapidly create cell lines and assays that were previously out of reach. They focus on high value drug targets that require the creation of complex multi-gene cell lines or the establishment of large panels of related receptors to determine specificity. They work mainly in pain relief, anxiety treatment and respiratory disorders.
Chromovert technology helps overcome roadblocks and challenges in a broad range of biomedical research. Among the most promising applications is its ability to enrich populations for cell therapy — a critical need in the clinical utilization of this field. Chromovert cell engineering can also be applied in the areas of stem cells, biologics production and flavors research.
Sophion Bioscience Inc.
Sophion Bioscience, Inc. is the US Subsidiary of Sophion Bioscience A/S (Denmark). Sophion Bioscience A/S was founded in July 2000, emerging from a successful research and development program at NeuroSearch. Sophion provides advanced products and integrated solutions for ion channel drug discovery. Sophion’s unique QPatch automated patch clamp system has integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The QPlate flow channel system enables fast liquid exchange and allows testing of multiple compounds or increasing concentrations on the same cell. The 48-channel QPatch HTX takes automated patch clamping to an even higher level. With its ability to generate thousands of high quality data points/day, QPatch HTX enables new screening paradigms in ion channel drug discovery and safety testing. The new QPatch 8/8X extends the QPatch family to six members.
In July 2011, Sophion Bioscience announced that it signed an agreement to join Biolin Scientific, a Swedish materials science company. Click here for more details on this agreement.
Ikano Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focusing on developing innovative nasally delivered pharmaceutical products with a; particular focus on drugs treating pain and disorders related to the central nervous system. This is a later stage start-up company who has had periods of growth and stagnation while it was trying to refine its technology, create new products and seek funding to grow the business. ITI has a fully integrated nasal drug delivery platform combining proprietary formulation research, clinical and regulatory development, specialized delivery systems, sterile manufacturing and packaging of nasal products.
Ikano Therapeutics dissolved its business after transferring the ownership of their ITI-111 nasal midazolam program for the treatment of acute epileptic seizure to Upsher-Smith Laboratories Inc.
Neurotez is a private corporation, formed to study and advance treatments for degenerative disorders of the central nervous system (CNS). Utilizing an integrated platform that spans activities from discovery to proof of concept clinical trials, Neurotez aims to identify and facilitate the commercialization of safe and efficacious CNS drugs. Neurotez’s lead biopharmaceutical is a potential therapeutic for Alzheimer’s disease patients, currently in the planning for clinical trials. Additional candidates, identified by exploiting proprietary screening technologies are in the discovery stage.